Daniel R. Hart

2020

In 2020, Daniel R. Hart earned a total compensation of $842.1K as Chief Financial Officer at Peregrine Pharmaceuticals, a 7% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$46,396
Option Awards$210,837
Salary$396,106
Stock Awards$142,433
Other$46,371
Total$842,143

Hart received $396.1K in salary, accounting for 47% of the total pay in 2020.

Hart also received $46.4K in non-equity incentive plan, $210.8K in option awards, $142.4K in stock awards and $46.4K in other compensation.

Rankings

In 2020, Daniel R. Hart's compensation ranked 9,294th out of 13,090 executives tracked by ExecPay. In other words, Hart earned more than 29.0% of executives.

ClassificationRankingPercentile
All
9,294
out of 13,090
29th
Division
Manufacturing
3,970
out of 5,620
29th
Major group
Chemicals And Allied Products
1,614
out of 2,253
28th
Industry group
Drugs
1,412
out of 1,953
28th
Industry
Pharmaceutical Preparations
1,035
out of 1,458
29th

Pay ratio

Daniel R. Hart's Pay$842,143
Median Employee's Pay$83,115
Pay Ratio

10

to 1

In 2020, the annual total compensation of Daniel R. Hart was $842,143.

The annual total compensation of the median employee at Peregrine Pharmaceuticals was $83,115.

The ratio of Daniel R. Hart's pay to the pay of median employee was therefore 10 to one.

Source: SEC filing on August 27, 2020.

Hart's colleagues

We found three more compensation records of executives who worked with Daniel R. Hart at Peregrine Pharmaceuticals in 2020.

2020

Mark Ziebell

Peregrine Pharmaceuticals

General Counsel

2020

Richard Hancock

Peregrine Pharmaceuticals

Chief Executive Officer

2020

Roger Lias

Peregrine Pharmaceuticals

Chief Executive Officer

News

You may also like